A multicenter prospective real-world cohort study of direct oral anticoagulant use for venous thromboembolism prophylaxis in nephrotic syndrome
Open Access
- 17 February 2026
- journal article
- research article
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Abstract
Nephrotic syndrome (NS), especially when associated with severe hypoalbuminia, confers a high risk of venous thromboembolism (VTE). While low-molecular-weiKeywords
All Related Versions
This publication has 21 references indexed in Scilit:
- Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K AntagonistsKidney International Reports, 2025
- Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective StudyKidney International Reports, 2025
- Direct Oral Anticoagulants in Patients With ESRD and Kidney TransplantationKidney International Reports, 2024
- Anticoagulation for the Prevention of Thrombotic Events in Nephrotic SyndromeKidney International Reports, 2024
- Risk of Arterial Thromboembolism, Venous Thromboembolism, and Bleeding in Patients with Nephrotic Syndrome: A Population-Based Cohort StudyThe American Journal of Medicine, 2022
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular DiseasesKidney International, 2021
- Albumin and bleed risk in rivaroxaban treated patientsJournal of Thrombosis and Thrombolysis, 2020
- Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndromeClinical and Experimental Nephrology, 2015
- Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathyKidney International, 2014
- Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritisKidney International, 2012